

DE047745.NP

AJ



(19)
Bundesrepublik Deutschland
Deutsches Patent- und Markenamt

(10) DE 103 16 701 A1 2004.11.04

(12)

Offenlegungsschrift

(21) Aktenzeichen: 103 16 701.3

(51) Int Cl. 7: C07H 21/00

(22) Anmeldetag: 09.04.2003

C12Q 1/68, C07K 14/435, A61K 38/17,
A61K 31/7088, A61P 11/00

(43) Offenlegungstag: 04.11.2004

(71) Anmelder:

Hinzmann, Bernd, Dr., 13127 Berlin, DE; Hermann,
Klaus, Dr., 12679 Berlin, DE; Heiden
Castaños-Vélez, Esmeralda, Dr., 10589 Berlin, DE

(72) Erfinder:

Mennerich, Detlev, Dr., 13347 Berlin, DE;
Brümmendorf, Thomas, 13347 Berlin, DE; Heiden,
Esmeralda, 13347 Berlin, DE; Hermann, Klaus,
13347 Berlin, DE; Kinnemann, Henrik, 13347
Berlin, DE; Li, Xinzong, 13347 Berlin, DE;
Röpcke, Stefan, 13347 Berlin, DE; Staub, Eike,
13347 Berlin, DE; Hinzmann, Bernd, 13347 Berlin,
DE; Rosenthal, André, 13347 Berlin, DE; Pilarsky,
Christian, 13347 Berlin, DE

Prüfungsantrag gemäß § 44 PatG ist gestellt.

Die folgenden Angaben sind den vom Anmelder eingereichten Unterlagen entnommen

(54) Bezeichnung: Humane Nukleinsäuresequenzen aus Bronchialkarzinomen

(57) Zusammenfassung: Die Erfindung betrifft neue humane Nukleinsäuresequenzen aus Bronchialkarzinomen, hierdurch codierte Proteine bzw. Peptide sowie deren Verwendungen im Zusammenhang mit der Diagnose und/oder Behandlung von Bronchialkrebs.

BEST AVAILABLE COPY

2/9/1

DIALOG(R) File 351:Derwent WPI

(c) 2006 The Thomson Corporation. All rts. reserv.

0014604435

WPI ACC NO: 2004-786403/200478

XRAM Acc No: C2004-275247

New nucleic acid, and derived proteins, useful for diagnosis of bronchial cancer and in screening for therapeutic and diagnostic agents

Patent Assignee: HEIDEN CASTANOS-VELEZ E (CAST-I); HEIDEN E (HEID-I); HERMANN K (HERM-I); HINZMANN B (HINZ-I); ROSENTHAL A (ROSE-I)

Inventor: BRUEMMENDORF T; HEIDEN E; HERMANN K; HINZMANN B; KINNEMANN H; LI X; MENNERICH D; PILARSKY C; ROEPCKE S; ROSENTHAL A; STAUB E

Patent Family (2 patents, 33 countries)

Patent	Application			
Number	Kind	Date	Number	Kind
DE 10316701	A1	20041104	DE 10316701	A
EP 1498424	A2	20050119	EP 200490140	A
				20030409 200478 B
				20040408 200506 E

Priority Applications (no., kind, date): DE 10316701 A 20030409

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
DE 10316701	A1	DE	381	0	
EP 1498424	A2	DE			

Regional Designated States,Original: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IT LI LT LU LV MC MK NL PL PT RO SE SI SK TR

Alerting Abstract DE A1

NOVELTY - Isolated nucleic acid (I) associated with bronchial cancer comprising 489 defined sequences given in the specification, is new.

DESCRIPTION - INDEPENDENT CLAIMS are also included for:

1. protein or peptide (II), preferably isolated, that contains a sequence encoded by (I) or consists of, or includes, any of 489 amino acid sequences, reproduced; and

2. methods for diagnosis or treatment of bronchial cancer that uses an agent (A) that binds to, or inhibits, (I) or (II).

ACTIVITY - Cytostatic.

No biological data given.

MECHANISM OF ACTION - Inhibiting expression or activity of tumor-associated proteins.

USE - (I), and proteins/peptides (II) encoded by them are used:

1. for detecting bronchial cancer or determining the risk of developing it; and

2. to screen for specific binding partners (A) of (I) and (II), where (A) are potentially useful as agents for treating or diagnosing bronchial cancer (claimed).

(I) and (II) can also be used for prognosis, detection of metastases and for secondary treatment (of tumors that have been stabilized or are no longer detectable).

ADVANTAGE - Detecting abnormal expression of (I) provides early diagnosis of bronchial cancers.

Technology Focus

BIOLOGY - Preferred Process: To detect bronchial cancer (or the risk of developing it) either a bronchial tissue sample is tested for differential

transcription of (I) or differential expression of (II), or (I) or (II) is detected in blood, serum or sputum. Particularly the method uses a detection substance (DS), preferably containing a reporter group, and binding of DS to (I) or (II) is determined (semi)quantitatively. Exemplified methods of detection are quantitative real-time PCR and reaction with labeled antibodies, -in vivo - or on tissue sections. To screen for (A), a test compound, or mixture, is contacted with (I) or (II) in a binding assay, and any compounds that bind are selected, optionally after deconvolution. For diagnosis of bronchial cancer, a labeled (A) is applied to test tissue, -in vivo - or -in vitro -, and any binding of (A) determined. The sample is assessed as containing tumor cells if a defined minimum value (over expression in tissue) or maximum value (underexpression) is found. Alternatively, serum or sputum samples are tested similarly.

Preferred Materials: Binding/inhibitory agents are:

1. antisense oligonucleotides, short interfering RNA or ribozymes directed against (I);
2. organic compounds of molecular weight below 5000, best 300, aptamers or (monoclonal) antibodies (Ab), preferably human or humanized, directed against (II);
3. anti-idiotypic non-human (monoclonal) antibodies directed against Ab; or
4. derivatives of (A)-(C) that contain a reporter group, cellular toxin, immunostimulant and/or radioisotope.

Isolation: RNA was isolated from bronchial tumor tissue and healthy tissue from the same patient; converted to cDNA and this used for transcription of biotinylated RNA. This was tested for hybridization to a gene chip and any genes showing differential expression between the two types of tissue were identified. Some (I)/(II) are associated with adenocarcinoma; others with lamellar epithelial carcinoma and others with both types of tumor.

Title Terms /Index Terms/Additional Words: NEW; NUCLEIC; ACID; DERIVATIVE; PROTEIN; USEFUL; DIAGNOSE; BRONCHIAL; CANCER; SCREEN; THERAPEUTIC; AGENT

Class Codes

International Classification (Main): C07H-021/00, C07K-014/47
(Additional/Secondary): A61K-031/7088, A61K-038/17, A61P-011/00,
C07K-014/435, C07K-016/18, C12Q-001/68, G01N-033/574

File Segment: CPI

DWPI Class: B04; D16

Manual Codes (CPI/A-M): B04-B04C2; B04-C01; B04-E01; B04-F02A; B04-G05;
B04-L04A; B04-N02A0E; B11-C07A; B11-C08E; B11-C08F2; B11-C08F4; B11-C10;
B12-K04A1; B12-K04E; B12-K04F; B14-H01B; B14-K01; B14-L01; B14-L06;
B14-S03; D05-A02B; D05-H07; D05-H08; D05-H09; D05-H11; D05-H12D1;
D05-H12D2; D05-H18B

Chemical Indexing

Chemical Fragment Codes (M6):

01 M905 P617 P631 P633 P820 Q233 Q505 R502 R515 R520 R521 R611 R613 R621
R622 R624 R627 R630 R631 R633 R637 R639

Original Publication Data by Authority

Germany

Publication No. DE 10316701 A1 (Update 200478 B)

Publication Date: 20041104

Humane Nukleinsauresequenzen aus Bronchialkarzinomen

Assignee: Hinzmann, Bernd, Dr., 13127 Berlin, DE (HINZ-I)

Hermann, Klaus, Dr., 12679 Berlin, DE (HERM-I)

Heiden Castanos-Velez, Esmeralda, Dr., 10589 Berlin, DE (CAST-I)

Inventor: Mennerich, Detlev, Dr., 13347 Berlin, DE

Brummendorf, Thomas, 13347 Berlin, DE

Heiden, Esmeralda, 13347 Berlin, DE

Hermann, Klaus, 13347 Berlin, DE

Kinnemann, Henrik, 13347 Berlin, DE

Li, Xinzong, 13347 Berlin, DE

Ropcke, Stefan, 13347 Berlin, DE

Staub, Eike, 13347 Berlin, DE

Hinzmann, Bernd, 13347 Berlin, DE

Rosenthal, Andre, 13347 Berlin, DE

Pilarsky, Christian, 13347 Berlin, DE

Language: DE (1381 pages, 0 drawings)

Application: DE 10316701 A 20030409 (Local application)

Original IPC: C07H-21/00(A) A61K-31/7088(B) A61K-38/17(B) A61P-11/00(B)

C07K-14/435(B) C12Q-1/68(B)

Current IPC: C07H-21/00(A) A61K-31/7088(B) A61K-38/17(B) A61P-11/00(B)

C07K-14/435(B) C12Q-1/68(B)

Original Abstract: Die Erfindung betrifft neue humane Nukleinsauresequenzen aus Bronchialkarzinomen, hierdurch codierte Proteine bzw. Peptide sowie deren Verwendungen im Zusammenhang mit der Diagnose und/oder Behandlung von Bronchialkrebs.

Claim:

1. Nukleinsaure, insbesondere isolierte Nukleinsaure, enthaltend oder bestehend aus einer Nukleinsauresequenz gemass einer der Sequenzen Seq.-ID 1 bis 489.

EPO

Publication No. EP 1498424 A2 (Update 200506 E)

Publication Date: 20050119

**Humane Nukleinsauresequenzen aus Bronchialkarzinomen

Human nucleic acid sequences from lung tumours

Acides nucleiques derivees du cancer bronchopulmonaire**

Assignee: Hinzmann, Bernd, Dr., Saupeweg 10, 13127 Berlin, DE (HINZ-I)

Hermann, Klaus Dr., Zuhlsdorfer Str. 43, 12679 Berlin, DE (HERM-I)

Heiden, Esmeralda, Tauroggenerstr. 8, 10589 Berlin, DE (HEID-I)

Rosenthal, Andre, Prof., Waldmullerstrasse 6, 14482 Potsdam, DE (ROSE-I)

Inventor: Rosenthal, Andre, Prof. Dr., Waldmullerstrasse 6, 14482 Potsdam, DE

Hermann, Klaus, Dr., Zuhlsdorfer Strasse 43, 12679 Berlin, DE

Heiden, Esmeralda, Dr., Tauroggenerstrasse 8, 10589 Berlin, DE

Pilarsky, Christian, Dr., Wallotstrasse 35, 01309 Dresden, DE

Brummendorf, Thomas, Dr., Rebgasse 18, 79540 Lorrach, DE

Staub, Eike, Binzstrasse 12, 13189 Berlin, DE

Ropcke, Stefan, Brentanostrasse 35, 12163 Berlin, DE

Mennerich, Detlev, Dr., Waldstrasse 17, 10551 Berlin, DE

Kinnemann, Henrik, Dr., Nordhauser Strasse 24, 10589 Berlin, DE

Li, Xinzong, Dr., c/o Dept. of Computing, Imperial College of London, 180 Queen's Gate, London SW7 2BZ, GB

Language: DE

Application: EP 200490140 A 20040408 (Local application)

Priority: DE 10316701 A 20030409

Designated States: (Regional Original) AL AT BE BG CH CY CZ DE DK EE ES FI

FR GB GR HR HU IE IT LI LT LU LV MC MK NL PL PT RO SE SI SK TR

Original IPC: C07K-14/47(A) C07K-16/18(B) C12Q-1/68(B) G01N-33/574(B)

Current IPC: C07K-14/47(A) C07K-16/18(B) C12Q-1/68(B) G01N-33/574(B)

Original Abstract: Die Erfindung betrifft neue humane Nukleinsauresequenzen

aus Bronchialkarzinomen, hierdurch codierte Proteine bzw. Peptide sowie deren Verwendungen im Zusammenhang mit der Diagnose und/oder Behandlung von Bronchialkrebs.

Claim:

1. Nukleinsaure, insbesondere isolierte Nukleinsaure, enthaltend oder bestehend aus einer Nukleinsauresequenz gemass einer der Sequenzen Seq.-ID 1 bis 489.

?